Aerovate Therapeutics (AVTE) Competitors $22.21 -1.25 (-5.33%) As of 05/22/2026 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsDividendFinancialsInsider TradesOptions ChainOwnershipSEC FilingsTrendsBuy This Stock AVTE vs. MOR, KLRA, GPCR, ARQT, and IRONShould you buy Aerovate Therapeutics stock or one of its competitors? MarketBeat compares Aerovate Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Aerovate Therapeutics include MorphoSys (MOR), Kailera Therapeutics (KLRA), Structure Therapeutics (GPCR), Arcutis Biotherapeutics (ARQT), and Disc Medicine (IRON). These companies are all part of the "pharmaceutical products" industry. AVTE vs. MORAVTE vs. KLRAAVTE vs. GPCRAVTE vs. ARQTAVTE vs. IRONHow does Aerovate Therapeutics compare to MorphoSys?Aerovate Therapeutics (NASDAQ:AVTE) and MorphoSys (NASDAQ:MOR) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, risk, valuation, media sentiment, institutional ownership, earnings and profitability. Does the media refer more to AVTE or MOR? In the previous week, Aerovate Therapeutics' average media sentiment score of 0.00 equaled MorphoSys'average media sentiment score. Company Overall Sentiment Aerovate Therapeutics Neutral MorphoSys Neutral Which has higher earnings & valuation, AVTE or MOR? Aerovate Therapeutics has higher earnings, but lower revenue than MorphoSys. Aerovate Therapeutics is trading at a lower price-to-earnings ratio than MorphoSys, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAerovate TherapeuticsN/AN/A-$75.52M-$1.70N/AMorphoSys$238.28M11.99-$205.35M-$3.48N/A Is AVTE or MOR more profitable? Aerovate Therapeutics has a net margin of 0.00% compared to MorphoSys' net margin of -226.79%. Aerovate Therapeutics' return on equity of -90.19% beat MorphoSys' return on equity.Company Net Margins Return on Equity Return on Assets Aerovate TherapeuticsN/A -90.19% -77.47% MorphoSys -226.79%-694.31%-22.55% Do institutionals & insiders believe in AVTE or MOR? 18.4% of MorphoSys shares are held by institutional investors. 24.9% of Aerovate Therapeutics shares are held by company insiders. Comparatively, 0.1% of MorphoSys shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Which has more volatility and risk, AVTE or MOR? Aerovate Therapeutics has a beta of 0.95, suggesting that its share price is 5% less volatile than the broader market. Comparatively, MorphoSys has a beta of 1.2, suggesting that its share price is 20% more volatile than the broader market. SummaryAerovate Therapeutics and MorphoSys tied by winning 5 of the 10 factors compared between the two stocks.How does Aerovate Therapeutics compare to Kailera Therapeutics?Kailera Therapeutics (NASDAQ:KLRA) and Aerovate Therapeutics (NASDAQ:AVTE) are both pharmaceutical preparations industry companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, analyst recommendations, risk, media sentiment, earnings and dividends. Does the media refer more to KLRA or AVTE? In the previous week, Kailera Therapeutics had 2 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 2 mentions for Kailera Therapeutics and 0 mentions for Aerovate Therapeutics. Kailera Therapeutics' average media sentiment score of 0.00 equaled Aerovate Therapeutics'average media sentiment score. Company Overall Sentiment Kailera Therapeutics Neutral Aerovate Therapeutics Neutral Do analysts prefer KLRA or AVTE? Kailera Therapeutics currently has a consensus price target of $42.75, suggesting a potential upside of 101.94%. Given Kailera Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Kailera Therapeutics is more favorable than Aerovate Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Kailera Therapeutics 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.00Aerovate Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has stronger earnings and valuation, KLRA or AVTE? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKailera TherapeuticsN/AN/AN/AN/AN/AAerovate TherapeuticsN/AN/A-$75.52M-$1.70N/A Is KLRA or AVTE more profitable? Kailera Therapeutics' return on equity of 0.00% beat Aerovate Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Kailera TherapeuticsN/A N/A N/A Aerovate Therapeutics N/A -90.19%-77.47% SummaryKailera Therapeutics beats Aerovate Therapeutics on 7 of the 7 factors compared between the two stocks.How does Aerovate Therapeutics compare to Structure Therapeutics?Aerovate Therapeutics (NASDAQ:AVTE) and Structure Therapeutics (NASDAQ:GPCR) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, media sentiment, profitability, analyst recommendations and risk. Do analysts rate AVTE or GPCR? Structure Therapeutics has a consensus target price of $109.25, indicating a potential upside of 178.77%. Given Structure Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Structure Therapeutics is more favorable than Aerovate Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aerovate Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Structure Therapeutics 2 Sell rating(s) 1 Hold rating(s) 13 Buy rating(s) 3 Strong Buy rating(s) 2.89 Which has more risk & volatility, AVTE or GPCR? Aerovate Therapeutics has a beta of 0.95, indicating that its stock price is 5% less volatile than the broader market. Comparatively, Structure Therapeutics has a beta of -1.31, indicating that its stock price is 231% less volatile than the broader market. Does the media refer more to AVTE or GPCR? In the previous week, Structure Therapeutics had 2 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 2 mentions for Structure Therapeutics and 0 mentions for Aerovate Therapeutics. Structure Therapeutics' average media sentiment score of 0.68 beat Aerovate Therapeutics' score of 0.00 indicating that Structure Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Aerovate Therapeutics Neutral Structure Therapeutics Positive Which has higher valuation & earnings, AVTE or GPCR? Structure Therapeutics is trading at a lower price-to-earnings ratio than Aerovate Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAerovate TherapeuticsN/AN/A-$75.52M-$1.70N/AStructure TherapeuticsN/AN/A-$141.20M-$0.87N/A Is AVTE or GPCR more profitable? Structure Therapeutics' return on equity of -24.91% beat Aerovate Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Aerovate TherapeuticsN/A -90.19% -77.47% Structure Therapeutics N/A -24.91%-23.67% Do insiders and institutionals believe in AVTE or GPCR? 91.8% of Structure Therapeutics shares are held by institutional investors. 24.9% of Aerovate Therapeutics shares are held by insiders. Comparatively, 5.6% of Structure Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. SummaryStructure Therapeutics beats Aerovate Therapeutics on 10 of the 14 factors compared between the two stocks.How does Aerovate Therapeutics compare to Arcutis Biotherapeutics?Aerovate Therapeutics (NASDAQ:AVTE) and Arcutis Biotherapeutics (NASDAQ:ARQT) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, dividends, valuation, profitability, risk, earnings, institutional ownership and media sentiment. Does the media favor AVTE or ARQT? In the previous week, Aerovate Therapeutics' average media sentiment score of 0.00 equaled Arcutis Biotherapeutics'average media sentiment score. Company Overall Sentiment Aerovate Therapeutics Neutral Arcutis Biotherapeutics Neutral Do analysts prefer AVTE or ARQT? Arcutis Biotherapeutics has a consensus target price of $34.00, indicating a potential upside of 62.99%. Given Arcutis Biotherapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Arcutis Biotherapeutics is more favorable than Aerovate Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aerovate Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Arcutis Biotherapeutics 1 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.50 Is AVTE or ARQT more profitable? Aerovate Therapeutics has a net margin of 0.00% compared to Arcutis Biotherapeutics' net margin of -0.57%. Arcutis Biotherapeutics' return on equity of -1.41% beat Aerovate Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Aerovate TherapeuticsN/A -90.19% -77.47% Arcutis Biotherapeutics -0.57%-1.41%-0.59% Which has more volatility & risk, AVTE or ARQT? Aerovate Therapeutics has a beta of 0.95, indicating that its stock price is 5% less volatile than the broader market. Comparatively, Arcutis Biotherapeutics has a beta of 1.58, indicating that its stock price is 58% more volatile than the broader market. Which has higher earnings and valuation, AVTE or ARQT? Arcutis Biotherapeutics has higher revenue and earnings than Aerovate Therapeutics. Arcutis Biotherapeutics is trading at a lower price-to-earnings ratio than Aerovate Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAerovate TherapeuticsN/AN/A-$75.52M-$1.70N/AArcutis Biotherapeutics$376.07M6.94-$16.14M-$0.03N/A SummaryArcutis Biotherapeutics beats Aerovate Therapeutics on 9 of the 11 factors compared between the two stocks.How does Aerovate Therapeutics compare to Disc Medicine?Disc Medicine (NASDAQ:IRON) and Aerovate Therapeutics (NASDAQ:AVTE) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, valuation, media sentiment, analyst recommendations, institutional ownership, profitability and earnings. Do insiders & institutionals hold more shares of IRON or AVTE? 83.7% of Disc Medicine shares are held by institutional investors. 3.8% of Disc Medicine shares are held by insiders. Comparatively, 24.9% of Aerovate Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Do analysts prefer IRON or AVTE? Disc Medicine presently has a consensus price target of $105.30, suggesting a potential upside of 57.59%. Given Disc Medicine's stronger consensus rating and higher probable upside, equities research analysts clearly believe Disc Medicine is more favorable than Aerovate Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Disc Medicine 1 Sell rating(s) 1 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.75Aerovate Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has more risk & volatility, IRON or AVTE? Disc Medicine has a beta of 0.93, meaning that its stock price is 7% less volatile than the broader market. Comparatively, Aerovate Therapeutics has a beta of 0.95, meaning that its stock price is 5% less volatile than the broader market. Does the media prefer IRON or AVTE? In the previous week, Disc Medicine had 5 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 5 mentions for Disc Medicine and 0 mentions for Aerovate Therapeutics. Disc Medicine's average media sentiment score of 0.60 beat Aerovate Therapeutics' score of 0.00 indicating that Disc Medicine is being referred to more favorably in the media. Company Overall Sentiment Disc Medicine Positive Aerovate Therapeutics Neutral Which has stronger earnings & valuation, IRON or AVTE? Aerovate Therapeutics is trading at a lower price-to-earnings ratio than Disc Medicine, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDisc MedicineN/AN/A-$212.18M-$6.62N/AAerovate TherapeuticsN/AN/A-$75.52M-$1.70N/A Is IRON or AVTE more profitable? Disc Medicine's return on equity of -36.94% beat Aerovate Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Disc MedicineN/A -36.94% -33.88% Aerovate Therapeutics N/A -90.19%-77.47% SummaryDisc Medicine beats Aerovate Therapeutics on 8 of the 13 factors compared between the two stocks. Get Aerovate Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AVTE and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding AVTE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AVTE vs. The Competition ExportMetricAerovate TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$643.76M$927.43M$6.45B$12.34BDividend YieldN/A4.84%2.76%5.28%P/E Ratio-7.431.4621.2225.65Price / SalesN/A119.63553.9286.28Price / CashN/A20.0743.4956.67Price / Book5.617.5910.377.14Net Income-$75.52M-$3.64M$3.57B$335.98M7 Day Performance-4.90%1.93%6.01%3.56%1 Month Performance-11.09%76.78%3.52%2.54%1 Year Performance215.93%126.62%34.13%35.05% Aerovate Therapeutics Competitors List ExportCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AVTEAerovate TherapeuticsN/A$22.21-5.3%N/A+215.9%$643.76MN/AN/A20High Trading VolumeMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28MN/A730News CoverageKLRAKailera Therapeutics4.5595 of 5 stars$22.30-2.7%$42.75+91.7%N/A$2.76BN/AN/A145Quiet Period ExpirationGPCRStructure Therapeutics3.0279 of 5 stars$37.84-1.3%$109.25+188.7%+59.6%$2.71BN/AN/A136ARQTArcutis Biotherapeutics2.7127 of 5 stars$20.69-2.6%$34.00+64.3%+49.2%$2.66B$376.07MN/A150 Related Companies and Tools Related Companies MorphoSys Competitors Kailera Therapeutics Competitors Structure Therapeutics Competitors Arcutis Biotherapeutics Competitors Disc Medicine Competitors Vera Therapeutics Competitors Immunome Competitors Nanobiotix Competitors Ultragenyx Pharmaceutical Competitors Tarsus Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:AVTE) was last updated on 5/25/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | SponsoredSatellite Images Spot Potential $10 Trillion Discovery'Dark Energy': Elon Musk's Next Potential $10 Trillion Move A highly secure site in West Texas now houses a...Altimetry | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aerovate Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aerovate Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
